Ghrelin Boosts Brain Recovery and New Neuron Growth After Stroke
Background
Stroke is a leading cause of long-term disability, resulting in significant neurological deficits due to brain tissue damage. While acute treatments exist, effective strategies for promoting recovery in the chronic phase (weeks to months post-stroke) are severely limited. This study addresses the critical need for interventions that can enhance brain repair and functional recovery long after the initial ischemic event.
Results
Ghrelin-treated mice demonstrated significantly improved neurological outcomes compared to controls. Behavioral assessments revealed a 45% reduction in neurological deficit scores in the ghrelin group by day 28 (p<0.001), indicating substantial functional recovery. > The most impactful finding was a 2.8-fold increase in the number of newly generated neurons (neurogenesis) in the peri-infarct region (the area surrounding the stroke damage) of ghrelin-treated brains compared to controls (p<0.0001). Furthermore, immunohistochemical analysis showed a 35% increase in synaptic density and a 20% decrease in glial scar volume in the ghrelin-treated group, suggesting enhanced brain plasticity and reduced inhibitory scarring. These findings collectively point to ghrelin's potent neurorestorative effects.
Why It Matters
This study provides compelling evidence for ghrelin's ability to promote significant neurological recovery and neurogenesis in the chronic phase after stroke. Its capacity to stimulate new neuron formation and improve functional outcomes long after the initial injury is particularly promising, addressing a major unmet clinical need. These findings suggest ghrelin could be developed into a novel therapeutic strategy to enhance long-term recovery for stroke survivors. Future research should focus on elucidating the precise molecular mechanisms and progressing towards human clinical trials (Phase I/II) to validate these effects.